NASDAQ •
Healthcare •
Biotechnology •
Quote as of 05/15/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization21,113 mln
Float542 mln
Earnings Date07/01/2026
Piotroski F-Score
2
/ 9
Weak
Beneish M-Score
-3.79
Highly reliable
1-Year Forecast
35.71
Attractive
Relative Strength
85
/ 100
Strongly outperforming
Debt / Equity
0.03
Debt-free
ROE
-17.70
Negative
Business Description
Roivant Sciences is a London-based biopharmaceutical company founded in 2014 that discovers, develops, and brings to market new medicines and drug delivery technologies. The company is advancing several treatment candidates targeting autoimmune and inflammatory conditions such as rheumatoid arthritis, lupus, and myasthenia gravis, as well as pulmonary hypertension linked to lung disease. Roivant also develops platforms designed to improve how medicines are delivered into the body.
